{"id":11317,"date":"2018-08-23T13:22:40","date_gmt":"2018-08-23T11:22:40","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2021\/bm%e2%80%91t-invests-in-world-leading-enzyme-company\/"},"modified":"2021-01-19T17:41:37","modified_gmt":"2021-01-19T16:41:37","slug":"bm-t-invests-in-world-leading-enzyme-company","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2018-en\/bm-t-invests-in-world-leading-enzyme-company\/","title":{"rendered":"bm\u2011t invests in world leading enzyme company"},"content":{"rendered":"<p><strong>c\u2011LEcta, a world-lead\u00ading biotech\u00adnol\u00adogy com\u00adpany focused on enzyme engi\u00adneer\u00ading and appli\u00adca\u00adtions in reg\u00adu\u00adlated mar\u00adkets like food and pharma, has closed a financ\u00ading round with Capri\u00adcorn Ven\u00adture Part\u00adners and the Ger\u00adman invest\u00adment com\u00adpany bm|t. The cap\u00adi\u00adtal increase pro\u00advides the com\u00adpany with growth cap\u00adi\u00adtal as well as valu\u00adable access to an inter\u00adna\u00adtional network.&nbsp;<\/strong><\/p>\n<p>c\u2011LEcta already has a diver\u00adsi\u00adfied share\u00adholder struc\u00adture. In addi\u00adtion to the founder, Dr. Marc Struhalla, pri\u00advate indus\u00adtrial investors and Ger\u00adman insti\u00adtu\u00adtion\u00adals, the com\u00adpany has now expanded its cir\u00adcle of share\u00adhold\u00aders by attract\u00ading inter\u00adna\u00adtional investors. c\u2011LEcta has received growth cap\u00adi\u00adtal from two new share\u00adhold\u00aders. Lead investor, Capri\u00adcorn Ven\u00adture Part\u00adners, is an inde\u00adpen\u00addent, inter\u00adna\u00adtion\u00adally ori\u00adented invest\u00adment com\u00adpany, based in Leu\u00adven, Bel\u00adgium. Capri\u00adcorn invests in inno\u00adv\u00ada\u00adtive, tech\u00adnol\u00adogy dri\u00adven com\u00adpa\u00adnies and has a mul\u00adti\u00addis\u00adci\u00adpli\u00adnary team of expe\u00adri\u00adenced invest\u00adment pro\u00adfes\u00adsion\u00adals. Capri\u00adcorn invested through two funds, namely the Capri\u00adcorn Sus\u00adtain\u00adable Chem\u00adistry Fund NV and Quest for Growth NV. The Ger\u00adman invest\u00adment com\u00adpany bm|t invests in high-growth tech\u00adnol\u00adogy com\u00adpa\u00adnies led by entre\u00adpre\u00adneur\u00adial teams. bm|t invested via the MFT Mit\u00adtel\u00adstands-Fonds Th\u00fcrin\u00adgen GmbH &amp; Co. KG. These new funds are planned to be par\u00adtic\u00adu\u00adlarly invested in the approval, launch and scale-up of prod\u00aducts from the project pipeline, fur\u00adther devel\u00adop\u00adment of the pipeline as well as the expan\u00adsion of inter\u00adna\u00adtional sales.<\/p>\n<p>Mr. Lud\u00adwig Goris, Invest\u00adment Man\u00adager of Capri\u00adcorn, com\u00admented on the invest\u00adment in c\u2011LEcta: \u201cWe see that global mega trends and chal\u00adlenges in human nutri\u00adtion are paving the way for indus\u00adtrial biotech com\u00adpa\u00adnies like c\u2011LEcta. Since its foun\u00adda\u00adtion, c\u2011LEcta has built up a remark\u00adable track record of tech\u00adnol\u00adogy and prod\u00aduct devel\u00adop\u00adment and has been able to val\u00adi\u00addate that through a grow\u00ading cus\u00adtomer base of lead\u00ading pharma, chem\u00adi\u00adcal and food ingre\u00addi\u00adent com\u00adpa\u00adnies. In addi\u00adtion, we were impressed by the highly qual\u00adi\u00adfied team in Leipzig. Founder and CEO Dr. Marc Struhalla and his moti\u00advated team have cre\u00adated a great com\u00adpany that has arrived at an attrac\u00adtive inflec\u00adtion point where the cur\u00adrent prod\u00aduct pipeline forms the foun\u00adda\u00adtion for an accel\u00ader\u00adated growth curve. We are proud to lead this growth cap\u00adi\u00adtal round and con\u00adtribute to the suc\u00adcess of c\u2011LEcta.\u201d<\/p>\n<p>Kevin Reeder, CEO of bm|t added, \u201cbm|t, which has a sub\u00adstan\u00adtial life sci\u00adences port\u00adfo\u00adlio, is very opti\u00admistic about its invest\u00adment in c\u2011LEcta. The company\u00b4s strong team, track record of suc\u00adcess\u00adful devel\u00adop\u00adment, and a highly com\u00adpelling prod\u00aduct pipeline were extremely impres\u00adsive. We feel c\u2011LEcta is well-posi\u00adtioned to tran\u00adsi\u00adtion to a high-value biotech\u00adnol\u00adogy prod\u00aduct com\u00adpany.\u201d The two new investors expand the group of share\u00adhold\u00aders, which pre\u00advi\u00adously included the fol\u00adlow\u00ading investors: SHS Gesellschaft f\u00fcr Beteili\u00adgungs\u00adman\u00adage\u00adment mbH, High-Tech Gr\u00fcn\u00adder\u00adfonds Man\u00adage\u00adment GmbH, KfW Banken\u00adgruppe, Dr. Marc Struhalla, Warn\u00ading Beteili\u00adgungs GmbH, Dr. Bader Beteili\u00adgungs GmbH, and Arthur Stein\u00admetz Beteili\u00adgungs&nbsp;GmbH.<\/p>\n<p>In order to rein\u00adforce man\u00adage\u00adment and the board and sup\u00adport the antic\u00adi\u00adpated growth, Thomas Pfaadt (45) recently joined c\u2011LEcta as CFO. He enriches the com\u00adpany with his expe\u00adri\u00adence in cor\u00adpo\u00adrate finance and M&amp;A. Pre\u00advi\u00adously Thomas Pfaadt worked for a pri\u00advate equity-owned oper\u00ada\u00adtor of reha\u00adbil\u00adi\u00adta\u00adtion clin\u00adics as well as for a fam\u00adily-owned inte\u00adgrated health\u00adcare group. He also gained expe\u00adri\u00adences as an invest\u00adment banker and con\u00adsul\u00adtant with a strong focus on the health\u00adcare sec\u00adtor. He com\u00admented on what excites him about c\u2011LEcta: \u201cc\u2011LEcta is a young, lean, and dynamic com\u00adpany and a global player at the same time. We are fight\u00ading the seri\u00adous chal\u00adlenges of today\u2019s human nutri\u00adtion. A grow\u00ading pop\u00adu\u00adla\u00adtion and a grow\u00ading demand for healthy nat\u00adural food require solu\u00adtions from enzyme tech\u00adnolo\u00adgies that the chem\u00adi\u00adcal indus\u00adtry can\u00adnot pro\u00advide. We are pleased to have won these two new investors to finance our work in address\u00ading these large opportunities.\u201d<\/p>\n<p>c\u2011LEcta is a fully inte\u00adgrated biotech\u00adnol\u00adogy com\u00adpany based in Leipzig, Ger\u00admany, with focus on enzyme engi\u00adneer\u00ading and appli\u00adca\u00adtion in reg\u00adu\u00adlated mar\u00adkets like food and pharma. c\u2011LEcta cur\u00adrently employs around 60 peo\u00adple. The com\u00adpany is well diver\u00adsi\u00adfied and cov\u00aders a large part of the value chain from dis\u00adcov\u00adery to engi\u00adneer\u00ading to the com\u00admer\u00adcial pro\u00adduc\u00adtion of enzymes as well as the man\u00adu\u00adfac\u00adtur\u00ading of other high-qual\u00adity biotech\u00adnol\u00adogy prod\u00aducts, either as in-house devel\u00adop\u00adments or in close co\u00f6per\u00ada\u00adtion with the indus\u00adtry. Over the last five years, c\u2011LEcta has con\u00adducted more than 30 enzyme engi\u00adneer\u00ading projects with a suc\u00adcess rate of &gt;90%. Only a few weeks ago, the com\u00adpany announced a major break\u00adthrough as the first com\u00adpany to develop a process to enable the mass-pro\u00adduc\u00adtion of a plant-based sweet\u00adener with a real sugar-like taste. In addi\u00adtion, two fur\u00adther food ingre\u00addi\u00adent prod\u00aducts with high mar\u00adket poten\u00adtial are in an advanced devel\u00adop\u00adment stage and the project pipeline com\u00adprises sev\u00aderal promis\u00ading can\u00addi\u00addates address\u00ading the multi-bil\u00adlion-euro food ingre\u00addi\u00adents mar\u00adket. This growth financ\u00ading is intended to raise c\u2011LEcta to a new level and ele\u00advate the focused food ingre\u00addi\u00adents from the project pipeline to com\u00admer\u00adcial scale production.<\/p>\n<p>CEO Dr. Marc Struhalla com\u00admented on c\u2011LEcta\u2019s core tech\u00adnol\u00adogy and the cap\u00adi\u00adtal increase: \u00abThe per\u00adfor\u00admance require\u00adments for enzymes to be applied in indus\u00adtrial processes are in most cases very spe\u00adcific and vary from nat\u00adu\u00adrally occur\u00adring vari\u00ada\u00adtions. Enzymes there\u00adfore need to be adapted to indus\u00adtrial con\u00addi\u00adtions via enzyme engi\u00adneer\u00ading, and c\u2011LEcta owns one of the most effi\u00adcient tech\u00adnol\u00adogy plat\u00adforms in this area. For enzyme opti\u00admiza\u00adtion as well as for the devel\u00adop\u00adment of arti\u00adfi\u00adcial enzyme activ\u00adi\u00adties, we use patent-pro\u00adtected strate\u00adgies that are inspired by nature. The indus\u00adtrial appli\u00adca\u00adtion of these tech\u00adnolo\u00adgies holds great mar\u00adket poten\u00adtial. The finan\u00adcial strength and valu\u00adable inter\u00adna\u00adtional net\u00adwork that we have gained through this financ\u00ading round now offers us the oppor\u00adtu\u00adnity to develop the full poten\u00adtial of our tech\u00adnol\u00adogy and peo\u00adple. With Capri\u00adcorn Ven\u00adture Part\u00adners and bm|t, we get two active investors on board that can con\u00adtribute sub\u00adstan\u00adtially to our inter\u00adna\u00adtional growth ambi\u00adtions. Also, I am all the more pleased that our new CFO Thomas Pfaadt will sup\u00adport us in this endeavor. Our goal is that in the future c\u2011LEcta\u00b4s tech\u00adnol\u00adogy will be employed in many things we encounter in every\u00adday&nbsp;life.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About Capri\u00adcorn Ven\u00adture Partners:<\/strong><\/p>\n<p>Capri\u00adcorn Ven\u00adture Part\u00adners is an inde\u00adpen\u00addent Euro\u00adpean man\u00adager of ven\u00adture cap\u00adi\u00adtal and equity funds, invest\u00ading in inno\u00adv\u00ada\u00adtive Euro\u00adpean com\u00adpa\u00adnies with tech\u00adnol\u00adogy as com\u00adpet\u00adi\u00adtive advan\u00adtage. It is based in Leu\u00adven, Bel\u00adgium and licensed by the FSMA (the Finan\u00adcial Ser\u00advices and Mar\u00adkets Author\u00adity in Belgium).<\/p>\n<p><strong>About bm|t: <\/strong><\/p>\n<p>Erfurt-based, bm|t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh (bm|t) is the largest growth investor in the fed\u00aderal state of Thuringia, Ger\u00admany. bm\u2011t invests in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies with strong growth poten\u00adtial across all sec\u00adtors and phases of the cor\u00adpo\u00adrate lifecycle.<\/p>\n<p><strong>About c\u2011LEcta<\/strong><\/p>\n<p>c\u2011LEcta is a fully inte\u00adgrated world-lead\u00ading biotech\u00adnol\u00adogy com\u00adpany with focus on enzyme engi\u00adneer\u00ading and appli\u00adca\u00adtion in reg\u00adu\u00adlated mar\u00adkets like food and pharma. The com\u00adpany is located in Leipzig, Ger\u00admany, and has estab\u00adlished itself as a lead\u00ading player in the real\u00adiza\u00adtion of high-value biotech prod\u00aducts, either in the form of in-house devel\u00adop\u00adments or in close co\u00f6per\u00ada\u00adtion with indus\u00adtry. The com\u00adpany cur\u00adrently employs around 60 people.<\/p>\n<p>c\u2011LEcta deliv\u00aders cost-effi\u00adcient and sus\u00adtain\u00adable pro\u00adduc\u00adtion processes which open new mar\u00adkets and allow for bet\u00adter pen\u00ade\u00adtra\u00adtion of exist\u00ading mar\u00adkets. The com\u00adpany is char\u00adac\u00adter\u00adized by fast and effi\u00adcient devel\u00adop\u00adment of best-in-class biotech solu\u00adtions and a rapid and suc\u00adcess\u00adful mar\u00adket intro\u00adduc\u00adtion and com\u00admer\u00adcial\u00adiza\u00adtion of the result\u00ading prod\u00aducts. This enables c\u2011LEcta to lever\u00adage the unique poten\u00adtial of its core tech\u00adnolo\u00adgies. c\u2011LEcta has a proven track record of more than 10 suc\u00adcess\u00adfully com\u00admer\u00adcial\u00adized high-value indus\u00adtrial biotech products.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>c\u2011LEcta, a world-lead\u00ad\u00ading biotech\u00adnol\u00adogy com\u00adpany focused on enzyme engi\u00adneer\u00ading and appli\u00adca\u00adtions in reg\u00adu\u00adlated mar\u00adkets like food and pharma, has closed a financ\u00ading round with Capri\u00adcorn Ven\u00adture Part\u00adners and the Ger\u00adman invest\u00adment com\u00adpany bm|t. The cap\u00adi\u00adtal increase pro\u00advides the com\u00adpany with growth cap\u00adi\u00adtal as well as valu\u00adable access to an inter\u00adna\u00adtional net\u00adwork.&nbsp; c\u2011LEcta already has&nbsp;a&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":5395,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[147],"tags":[],"class_list":["post-11317","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2018-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=11317"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11317\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/5395"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=11317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=11317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=11317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}